Switch theme
Sign up to access all valuation multiples
Mabwell (Shanghai) Bioscience Co Ltd is engaged in the research and development, production and sales of therapeutic biological products.
2017
n/a
LTM Revenue $57.7M
LTM EBITDA -$90.3M
$1.5B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Mabwell has a last 12-month revenue (LTM) of $57.7M and a last 12-month EBITDA of -$90.3M.
In the most recent fiscal year, Mabwell achieved revenue of $27.7M and an EBITDA of -$117M.
Mabwell expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Mabwell valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $57.7M | XXX | $27.7M | XXX | XXX | XXX |
| Gross Profit | $51.3M | XXX | $23.7M | XXX | XXX | XXX |
| Gross Margin | 89% | XXX | 86% | XXX | XXX | XXX |
| EBITDA | -$90.3M | XXX | -$117M | XXX | XXX | XXX |
| EBITDA Margin | -157% | XXX | -423% | XXX | XXX | XXX |
| EBIT | -$125M | XXX | -$138M | XXX | XXX | XXX |
| EBIT Margin | -217% | XXX | -498% | XXX | XXX | XXX |
| Net Profit | -$125M | XXX | -$145M | XXX | XXX | XXX |
| Net Margin | -217% | XXX | -523% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $102M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Mabwell's stock price is CNY 24 (or $3).
Mabwell has current market cap of CNY 9.5B (or $1.3B), and EV of CNY 10.7B (or $1.5B).
See Mabwell trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.5B | $1.3B | XXX | XXX | XXX | XXX | $-0.31 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Mabwell has market cap of $1.3B and EV of $1.5B.
Mabwell's trades at 53.7x EV/Revenue multiple, and -12.7x EV/EBITDA.
Equity research analysts estimate Mabwell's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Mabwell has a P/E ratio of -10.5x.
See valuation multiples for Mabwell and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1.3B | XXX | $1.3B | XXX | XXX | XXX |
| EV (current) | $1.5B | XXX | $1.5B | XXX | XXX | XXX |
| EV/Revenue | 25.8x | XXX | 53.7x | XXX | XXX | XXX |
| EV/EBITDA | -16.5x | XXX | -12.7x | XXX | XXX | XXX |
| EV/EBIT | -11.9x | XXX | -10.8x | XXX | XXX | XXX |
| EV/Gross Profit | 29.0x | XXX | n/a | XXX | XXX | XXX |
| P/E | -10.5x | XXX | -9.1x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -8.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialMabwell's last 12 month revenue growth is 137%
Mabwell's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
Mabwell's rule of 40 is -597% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Mabwell's rule of X is 185% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Mabwell and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 137% | XXX | 161% | XXX | XXX | XXX |
| EBITDA Margin | -157% | XXX | -423% | XXX | XXX | XXX |
| EBITDA Growth | -68% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -597% | XXX | -286% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 185% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 39% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 392% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 584% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Mabwell acquired XXX companies to date.
Last acquisition by Mabwell was XXXXXXXX, XXXXX XXXXX XXXXXX . Mabwell acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Mabwell founded? | Mabwell was founded in 2017. |
| Where is Mabwell headquartered? | Mabwell is headquartered in China. |
| Is Mabwell publicy listed? | Yes, Mabwell is a public company listed on SHG. |
| What is the stock symbol of Mabwell? | Mabwell trades under 688062 ticker. |
| When did Mabwell go public? | Mabwell went public in 2022. |
| Who are competitors of Mabwell? | Similar companies to Mabwell include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Mabwell? | Mabwell's current market cap is $1.3B |
| What is the current revenue of Mabwell? | Mabwell's last 12 months revenue is $57.7M. |
| What is the current revenue growth of Mabwell? | Mabwell revenue growth (NTM/LTM) is 137%. |
| What is the current EV/Revenue multiple of Mabwell? | Current revenue multiple of Mabwell is 25.8x. |
| Is Mabwell profitable? | Yes, Mabwell is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Mabwell? | Mabwell's last 12 months EBITDA is -$90.3M. |
| What is Mabwell's EBITDA margin? | Mabwell's last 12 months EBITDA margin is -157%. |
| What is the current EV/EBITDA multiple of Mabwell? | Current EBITDA multiple of Mabwell is -16.5x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
